Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 05, 2017 07:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios Appoints Jacqualyn Fouse, Ph.D., to the Board of Directors

CAMBRIDGE, Mass., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced...
November 17, 2017 07:05 ET | Source: Agios Pharmaceuticals, Inc.

Agios Presents Updated Phase 1 Data from Dose Expansion Cohort of Ivosidenib (AG-120) in Patients with IDH1 Mutant Positive Glioma

- Durable Stable Disease and Reduction of Tumor Growth Rates Observed for Patients with Low Grade Glioma; Median Treatment Duration of 16 Months with 51% of Patients Still on Treatment – - Ivosidenib...
November 01, 2017 09:32 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Present New Data from PKR and IDH Programs at the 2017 ASH Annual Meeting

– First Data From Ivosidenib Phase 1 Expansion in R/R AML and Phase 1 Frontline AML Combination Studies to be Highlighted in Oral Presentations – – Company to Host Investor Event and Webcast on...
November 01, 2017 07:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios Reports Third Quarter 2017 Financial Results

IDHIFA® Approval for IDH2m R/R AML Validates Precision Medicine Approach; Ivosidenib NDA Submission for IDH1m R/R AML on Track for Year End 2017 First Expansion Data from Ivosidenib Phase 1 Trial in...
October 31, 2017 07:30 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Present at the 26th Annual Credit Suisse Healthcare Conference Tuesday, November 7, 2017

CAMBRIDGE, Mass., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced...
October 25, 2017 07:30 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Webcast Conference Call of Third Quarter 2017 Financial Results on November 1, 2017

CAMBRIDGE, Mass., Oct. 25, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced...
September 05, 2017 07:30 ET | Source: Agios Pharmaceuticals

Agios to Present at the Morgan Stanley 15th Annual Global Healthcare Conference Monday, September 11, 2017

CAMBRIDGE, Mass., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today...
August 08, 2017 07:01 ET | Source: Agios Pharmaceuticals

Agios Reports Second Quarter 2017 Financial Results

– IDHIFA® (enasidenib) Granted Approval from FDA as First Targeted Therapy for Patients with IDH2m R/R AML and First Product Approved from Agios’ Discovery Platform – – Trial Designs Finalized for...
August 03, 2017 16:01 ET | Source: Agios Pharmaceuticals

Agios to Present at the Canaccord Genuity 37th Annual Growth Conference Thursday, August 10, 2017

CAMBRIDGE, Mass., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced...
July 28, 2017 07:30 ET | Source: Agios Pharmaceuticals

Agios to Webcast Conference Call of Second Quarter 2017 Financial Results on August 8, 2017

CAMBRIDGE, Mass., July 28, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced...